OCUP - Ocuphire Pharma plummets 31% after diabetic retinopathy candidate fails mid-stage trial
- Ocuphire Pharma ( NASDAQ: OCUP ) is down 31% in after-hours trading after reporting that a phase 2 trial for an oral diabetic retinopathy candidate missed the primary endpoint.
- The primary endpoint for APX3330 was a a precedented endpoint for local administration of anti-VEGF intravitreal injections.
- Ocuphire ( OCUP ) noted that a key secondary endpoint binocular 3-step or more worsening of DRSS (diabetic retinopathy severity score) did reach statistical significance.
- The company plans to move ahead with an End-of-Phase 2 meeting with the US FDA .
- Seeking Alpha's Quant Rating views Ocuphire ( OCUP ) as a hold with high marks for momentum and revisions .
For further details see:
Ocuphire Pharma plummets 31% after diabetic retinopathy candidate fails mid-stage trial